Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2021-06-29 Capital/Financing Update
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a non-brokered private placement by BioVaxys Technology Corp. It details the terms of the private placement, including the number of units, price, and use of proceeds. There is no financial report, earnings data, or detailed financial statements included. The document is an update on a financing activity, specifically a capital raise. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is over 6000 characters, so it is not a brief announcement or a report publication announcement. Hence, the classification is CAP with high confidence.
2021-06-29 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that BioVaxys Technology Corp. received a positive FDA response for a Pre-IND (Investigational New Drug) review related to its CoviDTH clinical development program. It discusses regulatory interactions, clinical trial planning, and forward-looking statements about the company's vaccine development. There are no financial statements, detailed financial performance data, or comprehensive management analysis. The document is an announcement of a regulatory update rather than a full report or filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a certification or officer attestation. The content is primarily a regulatory update and company announcement about FDA feedback and clinical development plans. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2021-06-14 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the start of construction of a GMP facility for clinical supply production related to a planned ovarian cancer vaccine study. It contains no financial statements, no regulatory filings like 10-K or interim reports, no voting results, no management changes, no earnings data, and no detailed financial or governance information. It is a corporate announcement about operational progress and future plans, typical of a general regulatory announcement or news release. The document length is 7138 characters, which is sufficient for a detailed announcement but does not contain financial or regulatory report content. Therefore, the best fitting category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous corporate announcements that do not fit other specific categories.
2021-06-01 English
News release - English.pdf
Board/Management Information Classification · 70% confidence The document is a press release announcing the appointment of a Policy Advisor at BioVaxys Technology Corp. It contains no financial data, no regulatory filings, no voting results, no management or board changes beyond the appointment of an advisor, and no financial or operational report. It is a corporate announcement about personnel related to policy advisory, not a formal management change announcement of directors or senior executives. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. The closest relevant category is Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management. Although the appointment is of a Policy Advisor (not a director or senior management), this is the best fit given the categories provided. The document length is 7,214 characters, so it is not a brief announcement of a report publication. Therefore, the classification is MANG with moderate confidence due to the nature of the appointment being advisory rather than a formal board or senior management change.
2021-05-20 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that BioVaxys Technology Corp. has been uplisted from the OTC Pink Sheets to the OTCQB Venture Market. It discusses the implications of this uplisting for the company's stock trading and visibility, but does not contain any financial statements, detailed financial performance data, or regulatory filings. There is no indication that this is an annual report, earnings release, or any other detailed financial or regulatory document. The content is primarily an announcement about a change in the company's stock market listing status. Therefore, the most appropriate classification is a Regulatory Filing (RNS), as it is a general regulatory announcement that does not fit into more specific categories.
2021-05-19 English
News release - English.pdf
Regulatory Filings
2021-05-03 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.